OABI Strangle Strategy
OABI (OmniAb, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
OABI (OmniAb, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $239.4M, a beta of 0.62 versus the broader market, a 52-week range of 1.22-2.295, average daily share volume of 507K, a public-listing history dating back to 2021, approximately 114 full-time employees. These structural characteristics shape how OABI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.62 indicates OABI has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on OABI?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current OABI snapshot
As of May 15, 2026, spot at $2.19, ATM IV 239.10%, IV rank 46.57%, expected move 68.55%. The strangle on OABI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on OABI specifically: OABI IV at 239.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 68.55% (roughly $1.50 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated OABI expiries trade a higher absolute premium for lower per-day decay. Position sizing on OABI should anchor to the underlying notional of $2.19 per share and to the trader's directional view on OABI stock.
OABI strangle setup
The OABI strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With OABI near $2.19, the first option leg uses a $2.30 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed OABI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 OABI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.30 | N/A |
| Buy 1 | Put | $2.08 | N/A |
OABI strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
OABI strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on OABI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on OABI
Strangles on OABI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the OABI chain.
OABI thesis for this strangle
The market-implied 1-standard-deviation range for OABI extends from approximately $0.69 on the downside to $3.69 on the upside. A OABI long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current OABI IV rank near 46.57% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on OABI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, OABI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to OABI-specific events.
OABI strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. OABI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move OABI alongside the broader basket even when OABI-specific fundamentals are unchanged. Always rebuild the position from current OABI chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on OABI?
- A strangle on OABI is the strangle strategy applied to OABI (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With OABI stock trading near $2.19, the strikes shown on this page are snapped to the nearest listed OABI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are OABI strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the OABI strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 239.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a OABI strangle?
- The breakeven for the OABI strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current OABI market-implied 1-standard-deviation expected move is approximately 68.55%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on OABI?
- Strangles on OABI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the OABI chain.
- How does current OABI implied volatility affect this strangle?
- OABI ATM IV is at 239.10% with IV rank near 46.57%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.